California HealthCare Foundation (CHCF) has invested $1.5m in IRhythm Technologies, a US-based medical device maker backed by peers St Jude Medical and Kaiser Permanente’s corporate venturing units.

Alongside this investment, CHCF is planning to fund studies testing IRhythm’s products at two Californian hospitals.

Margaret Laws, director of the Innovations for the Uninsured Program at CHCF and manager of the CHCF Health Innovation Fund, said: “IRhythm’s Zio Patch technology [pictured] has the potential to increase access to timely diagnosis and care for patient populations in both rural and urban environments.

“The simplicity of their approach to ambulatory cardiac monitoring minimizes logistics, promotes increased patient compliance, and streamlines the process for patients and clinicians.”

CHCF said its $1.5m investment in IRhythm was its largest to date. Its other deals are: Lifewave ($950,000), Pipeline ($750,000), CareInSync ($500,000), DirecDerm ($240,000), Asthmapolis ($197,000) and Sirum ($46,000).

Kevin King, executive president of IRhythm since July after…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?